
Lantern Pharma (LTRN) Earnings Dates & Reports
Lantern Pharma (LTRN) Most Recent Earnings
Report Date
Period EndingQ3 2025
Est. EPS-$0.46
Actual EPS-$0.39
EarningsBeat
Lantern Pharma (LTRN) Earnings
View the latest Lantern Pharma (LTRN) earnings report, listen to the earnings call, and analyze historical earnings performance with AI-powered insights.
Start investing in Lantern Pharma (LTRN)
Order type
Buy in
Order amount
Est. shares
0 shares
Lantern Pharma (LTRN) Earnings per Share (EPS) History
Signup for full accessBrowse free
Lantern Pharma (LTRN) Latest Earnings
The value each LTRN share was expected to gain vs. the value each share gained.
Lantern Pharma (LTRN) reported its most recent earnings on for Q3 2025, posting earnings per share (EPS) of -$0.39. This exceeded analysts' expectations of -$0.46 by 15.22%, marking a Beat.
For comparison, Lantern Pharma reported EPS of -$0.42 in the same quarter last year.
The company is expected to announce its next earnings report on , with analysts projecting an EPS of -$0.45.
Lantern Pharma (LTRN) Earnings History
Lantern Pharma (LTRN) Earnings Related Price Changes
Earnings announcements may impact a stock’s price. This table highlights the Lantern Pharma’s price movement by comparing the day-before and day-after prices of recent earnings reports, along with the percentage change.
| Report date | Price 1D before | Price 1D after | Change |
|---|---|---|---|
| — | — | — | |
| — | — | — | |
| — | — | — | |
| — | — | — |
Lantern Pharma (LTRN) Earnings FAQs
Lantern Pharma (LTRN) last reported earnings on Nov 13, 2025 for Q3 2025, posting an EPS of -$0.39, which Beat the estimate of -$0.46 by 15.22%.
For Q3 2025, Lantern Pharma (LTRN) reported an EPS of -$0.39, exceeding analysts' estimate of -$0.46 by 15.22%.
For Q3 2025, Lantern Pharma (LTRN) Beat expectations with an actual EPS of -$0.39 vs. an estimated EPS of -$0.46.
Following the last earnings report on Nov 13, 2025, Lantern Pharma (LTRN)'s stock price moved — from — to —.
The next Lantern Pharma (LTRN) earnings call is scheduled for Mar. 26, 2026, where executives will discuss financial results and outlook.